Clinical Trials Directory

Trials / Completed

CompletedNCT04300179

Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt

Status
Completed
Phase
Study type
Observational
Enrollment
59 (actual)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to identify demographic \& disease characteristics in pediatric oncology patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT) \& treatment outcomes in these patients.

Detailed description

Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET), Both entities that currently comprise the same spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), were originally described as distinct clinicopathologic entities. Primitive neuroectodermal tumors (PNETs) first described in 1918 by Stout as a malignant tumor arising from major nerve. Later, in 1921, ES was described as an undifferentiated tumor involving the diaphysis of long bones. It was also reported to arise in soft tissue (extraosseous ES). EFT is aggressive malignant small round cell tumors of bone and soft-tissue that predominantly affecting children and young adults.

Conditions

Timeline

Start date
2020-07-07
Primary completion
2020-12-16
Completion
2020-12-16
First posted
2020-03-09
Last updated
2020-12-17

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04300179. Inclusion in this directory is not an endorsement.